Skip to main content
. 2020 Jun 20;2020:3759179. doi: 10.1155/2020/3759179

Table 4.

American Association for Cancer Research (AACR) (2014-2019) “hormone receptor positive” OR “HR+” OR “ER+” OR “PR+” OR “estrogen receptor positive”
American Society of Clinical Oncology (ASCO) Breast Cancer Symposium (2014-2018) breast cancer AND (“hormone receptor positive” OR “HR+” OR “ER+” OR “PR+” OR “estrogen receptor positive”)
San Antonio Breast Cancer Symposium (2014-2018) breast cancer AND (“hormone receptor positive” OR “HR+” OR “ER+” OR “PR+” OR “estrogen receptor positive”)
European CanCer Organisation (ECCO) (2015-2016) breast cancer AND (“hormone receptor positive” OR “HR+” OR “ER+” OR “PR+” OR “estrogen receptor positive”)
Abstract title: breast cancer
European Society for Medical Oncology (ESMO) (2014, 2016) breast cancer AND (“hormone receptor positive” OR “HR+” OR “ER+” OR “PR+” OR “estrogen receptor positive”)
Abstract title: breast cancer